Previous 10 | Next 10 |
NEW YORK, Jan. 29, 2020 (GLOBE NEWSWIRE) -- Intercept Pharmaceuticals, Inc. (Nasdaq:ICPT), a biopharmaceutical company focused on the development and commercialization of novel therapeutics to treat progressive non-viral liver diseases, today announced that it has completed patient enrollme...
Intercept Pharmaceuticals (NASDAQ: ICPT) is in the enviable position of many biotech companies. It boasts a marketed drug on pace to deliver more than $200 million in sales for 2019 and is anticipating an upcoming decision from the Food and Drug Administration that could grant it the fi...
Generally speaking, biotech stocks were one of the best places to put your money in 2019. The iShares Nasdaq Biotechnology ETF gained a stellar 25.2% last year, despite the political wrangling over prescription drug prices in the United States. Fortunately, this upward trend should continue un...
This past week, Intercept Pharmaceuticals ( ICPT ) was notified by the FDA that its PDUFA date for Ocaliva to treat patients with NASH would be delayed to June 26, 2020. However, any potential weakness or downtrend in the stock in the coming months should be viewed as a great buying opport...
A company with research centered around each of these divisions, like a cluster of trees each growing additional branches form its own trunk, will usually do much better than a company working on a number of unrelated new products which, if successful, will land it in several new industries ...
NEW YORK, Jan. 08, 2020 (GLOBE NEWSWIRE) -- Intercept Pharmaceuticals, Inc. (Nasdaq:ICPT), a biopharmaceutical company focused on the development and commercialization of novel therapeutics to treat progressive non-viral liver diseases, today announced that Mark Pruzanski, M.D., President a...
We've run through 10 different sectors or styles of investing in our year-end Marketplace Roundtable series. You can review the full list of roundtables at the end of this article in case you'd like to catch up on any specific angle. As we do every year, we conclude the series with the com...
The new year has a collection of challenges in store for the biotech sector and its investors, as pressure mounts from Washington on drug pricing practices. Along with talking points surrounding the upcoming presidential election in the US, several drug approvals and research developments wi...
Baxter International (NYSE: BAX ) upgraded to Outperform with a $94 (12% upside) price target at Evercore ISI. Shares up 1% premarket. More news on: Baxter International Inc., Henry Schein, Inc., Medtronic plc, Healthcare stocks news, Stocks on the move, , Read more ...
Welcome to a special New Year's Day edition of Seeking Alpha's Stocks to Watch series - a preview of some key events and catalysts to look for in the new year. A podcast of Stocks to Watch is available every Sunday on Seeking Alpha , Apple Podcasts , Stitcher and Spotify (click the highl...
News, Short Squeeze, Breakout and More Instantly...
Intercept Pharmaceuticals Inc. Company Name:
ICPT Stock Symbol:
NASDAQ Market:
Intercept Pharmaceuticals Inc. Website:
MORRISTOWN, N.J., May 09, 2024 (GLOBE NEWSWIRE) -- Intercept Pharmaceuticals, Inc., a biopharmaceutical company and wholly owned subsidiary of Alfasigma S.p.A. focused on the development and commercialization of novel therapeutics to treat rare and serious liver diseases, today announced five abs...
sNDA intended to satisfy post-marketing requirements to confirm a clinical benefit in patients with PBC Precedent-setting submission includes data from post-marketing studies COBALT and Study 401 as well as real-world evidence from a claims database and patient registries FDA has assign...
Data from two Phase 2 studies in PBC show combination of OCA + bezafibrate achieved biochemical remission (normalization of ALP, total bilirubin, GGT, ALT and AST) in 40-44% of patients in the first 12 weeks OCA 5 or 5-10 mg + bezafibrate 400 mg cohorts in both studies showed a >60% ...